What’s an OTC drugmaker worth in the race to the top of the consumer healthcare space? Potentially more than $5.3 billion, if that drugmaker is Belgium’s Omega Pharma.
The up-for-sale company has so far drawn interest from suitors including Perrigo ($PRGO) and Boehringer Ingelheim, and the big guns – Bayer and Sanofi ($SNY) – may get involved, too, Bloomberg‘s sources say. According to those sources, the sale – still in its early stages – could bring in more than €4 billion.
With €1.2 billion in first-half sales this year, Omega could add some top-line firepower for any drugmaker looking to build its presence in the consumer health arena. The company boasts about 2,000 brands, according to its website, including painkiller Solpadeine.
Bayer and Sanofi have both shown quite a bit of recent interest in doing just that. Marijn Dekkers, the German pharma’s CEO, has said many times that his company’s aim is to be the world’s OTC leader, a goal it furthered with a May deal to pick up Merck’s ($MRK) consumer unit for $14.2 billion.
Sanofi, too, has beefed up its consumer lineup considerably over the past several years, more than doubling its sales in that department between 2008 and 2012. That growth spurt included a $1.9 billion buyout of U.S.-based Chattem and a key OTC launch for allergy med Allegra.
Perrigo hasn’t shied away from M&A lately, either, though last year’s $8.6 billion deal for Irish drugmaker Elan ($ELN) didn’t further any OTC aims. Instead, the then-Michigan-based company picked up a new Dublin address in an inversion deal that slashed its tax rates.
By Carly Helfand
Source: Fierce Pharma
As Novo Nordisk gears up to disrupt the obesity market with its newly approved weight-loss drug Wegovy, it is teaming with retail pharmacy giant CVS Health on a new education and nutrition coaching program for people taking anti-obesity meds.
The terms of the deal were undisclosed, but Atreca received $6 million from the Gates Foundation in 2012 to discover potential treatments for malaria, tuberculosis and HIV. The foundation has also given grant money to other biopharmas exploring malaria treatments, including Exscientia, which secured $4.2 million last year for such work.
At the start of the last decade, the IPO markets weren’t receptive to biotech companies. But by 2013, public investment was pouring into the industry, drawn by scientific advances and boosted by the newfound interest of a broader range of investors. Ever since, biotechs and their backers have ridden a multi-year boom. Keep track of them as they happen with this database.